BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of ...
The report highlights that insulin-derived amyloidosis can mimic other injection-site reactions and should be considered when ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation ...
Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...
Vera Therapeutics stock rose on FDA acceptance of atacicept BLA for priority review in IgAN, a potential multi-billion dollar ...
MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
Fresenius Kabi, an Operating Company of Fresenius, and a leading provider of essential medicines and medical technologies, ...
FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting ...
The Brighterside of News on MSN
Antibody injections could replace slow IV drips in treating many diseases, MIT scientists find
Many patients endure hours-long infusions because antibody doses can exceed 100 milliliters, far beyond subcutaneous limits ...
Enable Injections closed a $215 million Series C financing in January 2022 led by Magnetar Capital, including Sanofi and multiple additional new institutional investors. Enable received significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback